The MDM2 gene, located at 12q15, when overexpressed, enhances the tumourigenic potential of cells.
The oncogene product forms a tight complex with the p53 tumour suppressor protein and can inhibit p53 mediated transactivation, leading to escape from p53 regulated growth control1. The Murine Double Minute 2 (MDM2) gene has been shown to be amplified in around 7% of human tumours2.
Many tumours overexpress MDM2, the most common being soft tissue tumours (20%), osteosarcomas (16%) and oesophageal carcinomas (13%)3. The use of FISH in well differentiated liposarcoma has been a valuable diagnostic tool4,5, whilst small-molecule MDM2 inhibitors that could act as innovative therapeutic tools have also been identified6.
1. Momanad J et al., Cell 1992;69(7):1237-45
2. Forslund et al., Mol Cancer Res. 2008 Feb;6(2):205-11
3. Momand J, Nuc Acid Res 1998;26(15):3453-9
4. Weaver J et al., Modern Path 2008;21(8):943-9
5. Sirvent N et al., Am J Surg Pathol 2007;31(10):1476-98
6. Vassilev LT, Trends Mol Med 2007;13(1):23-31
- Area of Interest*
- Glioma, Oesophageal Cancer, Lung Cancer, Sarcoma
This product is intended to be used on formalin-fixed paraffin-embedded (FFPE) tissues.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.